| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial V Heinemann, LF von Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, ... The lancet oncology 15 (10), 1065-1075, 2014 | 1999 | 2014 |
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of … S Stintzing, DP Modest, L Rossius, MM Lerch, LF von Weikersthal, ... The Lancet Oncology 17 (10), 1426-1434, 2016 | 470 | 2016 |
| Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 … C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ... The lancet oncology 16 (16), 1691-1699, 2015 | 459 | 2015 |
| Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, ... Leukemia 26 (3), 381-389, 2012 | 450 | 2012 |
| Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium M Von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek, K Hölig, ... Bone marrow transplantation 43 (3), 245-251, 2009 | 390 | 2009 |
| Manipulating immune responses with immunosuppressive agents that target NFAT A Kiani, A Rao, J Aramburu Immunity 12 (4), 359-372, 2000 | 372 | 2000 |
| Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease D Wolff, M Schleuning, S von Harsdorf, U Bacher, A Gerbitz, M Stadler, ... Biology of Blood and Marrow Transplantation 17 (1), 1-17, 2011 | 333 | 2011 |
| Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD D Wolff, A Gerbitz, F Ayuk, A Kiani, GC Hildebrandt, GB Vogelsang, ... Biology of Blood and Marrow Transplantation 16 (12), 1611-1628, 2010 | 311 | 2010 |
| Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia H Pfeifer, B Wassmann, W Bethge, J Dengler, M Bornhäuser, M Stadler, ... Leukemia 27 (6), 1254-1262, 2013 | 261 | 2013 |
| Down-regulation of IL-4 gene transcription and control of Th2 cell differentiation by a mechanism involving NFAT1 A Kiani, JPB Viola, AH Lichtman, A Rao Immunity 7 (6), 849-860, 1997 | 217 | 1997 |
| Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial S Stintzing, P Wirapati, HJ Lenz, D Neureiter, LF Von Weikersthal, ... Annals of Oncology 30 (11), 1796-1803, 2019 | 184 | 2019 |
| Regulation of interferon-γ gene expression by nuclear factor of activated T cells A Kiani, FJ Garcıa-Cózar, I Habermann, S Laforsch, T Aebischer, ... Blood, The Journal of the American Society of Hematology 98 (5), 1480-1488, 2001 | 157 | 2001 |
| Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK … V Heinemann, L Fischer von Weikersthal, T Decker, A Kiani, ... Journal of Clinical Oncology 31 (18_suppl), LBA3506-LBA3506, 2013 | 149 | 2013 |
| Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors … DP Modest, S Stintzing, LF von Weikersthal, T Decker, A Kiani, ... Journal of Clinical Oncology 33 (32), 3718-3726, 2015 | 148 | 2015 |
| Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study S Stintzing, L Miller-Phillips, DP Modest, LF von Weikersthal, T Decker, ... European Journal of Cancer 79, 50-60, 2017 | 146 | 2017 |
| Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation M Bornhäuser, U Oelschlaegel, U Platzbecker, G Bug, K Lutterbeck, ... haematologica 94 (11), 1613, 2009 | 137 | 2009 |
| FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial V Heinemann, LF von Weikersthal, T Decker, A Kiani, F Kaiser, ... British journal of cancer 124 (3), 587-594, 2021 | 120 | 2021 |
| Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? C Röllig, M Kramer, C Schliemann, JH Mikesch, B Steffen, A Krämer, ... Blood, The Journal of the American Society of Hematology 136 (7), 823-830, 2020 | 108 | 2020 |
| Regulation of allergic inflammation and eosinophil recruitment in mice lacking the transcription factor NFAT1: role of interleukin-4 (IL-4) and IL-5 JPB Viola, A Kiani, PT Bozza, A Rao Blood, The Journal of the American Society of Hematology 91 (7), 2223-2230, 1998 | 106 | 1998 |
| Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population S Stintzing, DP Modest, LF von Weikersthal, T Decker, A Kiani, ... Annals of Oncology 25, v1, 2014 | 90 | 2014 |
